Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2023-12-25 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
关于新增重大诉讼事项的公告
Legal Proceedings Report Classification · 100% confidence The document is a detailed announcement from 广州市香雪制药股份有限公司 regarding new significant litigation matters. It includes specifics about the parties involved, the nature of the lawsuit, amounts involved, and the current status of the case. It also provides a comprehensive list of other ongoing litigation cases with details on progress and amounts. The document is clearly a legal proceedings update, focusing on lawsuits and their impact on the company. There is no indication that this is a full annual or interim financial report, audit report, or any other type of financial or governance report. The content matches the description of a Legal Proceedings Report, which covers updates on significant lawsuits and regulatory actions involving the company.
2023-12-25 Chinese
第九届监事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the supervisory board of Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the resolution passed in their 12th meeting of the 9th supervisory board. The key content is the approval of a proposal to change the company's accounting firm. It mentions that the proposal will be submitted to the shareholders' meeting for approval. The document is short (643 characters) and serves as an official announcement of a board decision rather than a full report or detailed financial data. It does not contain financial statements or detailed audit results, so it is not an Audit Report (AR) or Annual Report (10-K). It is also not a Management Report or any other detailed report type. The document fits best under Board/Management Information (MANG) as it relates to a board-level decision about auditor change. Confidence is high due to clear keywords and document purpose.
2023-12-13 Chinese
独立董事关于第九届董事会第十七次会议相关事项的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions regarding the change of the company's accounting firm. It references relevant laws and company regulations and expresses an independent judgment on the matter. The document is short (485 characters) and does not contain financial statements or detailed audit results. It is related to audit matters but is not a standalone audit report or full annual report. It is more of a regulatory or compliance announcement related to audit firm change, fitting best under Regulatory Filings (RNS).
2023-12-13 Chinese
关于召开2023年第四次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2023 fourth extraordinary general meeting of shareholders for Guangzhou Xiangxue Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items (including a proposal to change the accounting firm), registration details, and attachments such as proxy forms and shareholder registration forms. The document does not contain financial statements or results but is a formal announcement to shareholders about the meeting and voting process. It is not a report itself but a meeting notice and related procedural information. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2023-12-13 Chinese
第九届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It includes details about the change of the company's auditor and the scheduling of an extraordinary general meeting. The document is short (855 characters) and primarily reports on board decisions and meeting arrangements rather than presenting financial data or detailed reports. It does not contain financial statements or detailed audit results, so it is not an Annual Report (10-K) or Audit Report (AR). It is not a full management report or earnings release. The content fits best under Board/Management Information (MANG) as it announces board meeting resolutions and management decisions.
2023-12-13 Chinese
独立董事关于第九届董事会第十七次会议相关事项的独立意见
Audit Report / Information Classification · 90% confidence The document is an independent opinion from the independent directors regarding the change of the company's accounting firm for the 2023 audit. It references compliance with laws and company regulations and discusses the audit firm appointment process. The document is short (599 characters) and does not contain actual financial statements or detailed audit results. It is an opinion related to audit matters but not a full audit report or annual report. It is also not a regulatory filing or announcement of a report publication. Given the content, it fits best under Audit Report / Information (AR) as it relates to audit firm appointment and audit-related opinions. FY 2023
2023-12-13 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.